Cytori Therapeutics - Independent Study On Scleroderma Shows Great Results

| About: Cytori Therapeutics (CYTX)
This article is now exclusive for PRO subscribers.

Just a short note on interesting company news from Cytori Therapeutics (NASDAQ:CYTX) that was not accompanied by a formal press release.

An independent study of 12 patients in France, evaluating Cytori's cell therapy, showed great results on treating patients with a debilitating disease called scleroderma. Scleroderma is a chronic autoimmune disorder that causes fibrosis of the skin, destructive changes in blood vessels and involvement of multiple organ systems as the result of an overproduction of collagen in the skin and vital organs. People suffering from scleroderma very often have disabling disease involving the hands. Here is a link to the "Investor's Note" on Cytori's website in lieu of a formal release. Importantly for any clinical study, the p values for this small study for all end points are all "P < .001", a very strong statistical indication that the cause and effect relationship of the therapy was not by chance but as a direct result of the therapy.

Scleroderma is an autoimmune disease. An autoimmune disorder is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. According to the NIH, there are over 80 distinct diseases in this category, from Type 1 Diabetes to Rheumatoid Arthritis.

Adipose Derived Regenerative Cells (ADRCs), the product of Cytori's medical device technology, have shown terrific therapeutic value over multiple diseases. This is just one more example.

Disclosure: I am long CYTX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.